Suppr超能文献

α干扰素与OK-432(链球菌制剂)序贯联合治疗晚期肾细胞癌

[Sequential combination therapy with alpha interferon and OK-432 (streptococcal preparation) against advanced renal cell carcinoma].

作者信息

Marumo K, Mura M, Deguchi N, Baba S, Jitsukawa S, Nakazono M, Tazaki H

出版信息

Gan To Kagaku Ryoho. 1986 Jul;13(7):2434-9.

PMID:3729498
Abstract

Renal cell carcinoma (RCC) is one of the most insensitive urologic tumors to either radiotherapy or anticancer chemotherapy. Recently, effectiveness of interferon (IFN) against RCC has been reported. However, because this effect is somewhat limited, a new modality of treatment is needed. We herein report our experience with IFN and OK-432, a streptococcal preparation for patients with advanced RCC. Twenty patients aged from 26 years to 75 years, with an average age of 52.3 years, were entered into this study. Intramuscular injection of human lymphoblastoid interferon (HLBI) at a dose of 3 X 10(6) units was given daily for between 4 and 76 weeks. Treatment with OK-432 then followed HLBI, unless the patient achieved CR or the status of the patient seriously deteriorated during the initial treatment with HLBI. OK-432 was given to 12 patients at a dose of 5KE (Klinische Einheit) 2 days a week for between 10 and 64 weeks. Effectiveness of HLBI therapy was 20% (CR 1 case, MR 3 cases, NC 11 cases, PD 5 cases). With adjuvant OK-432 therapy for patients whose disease proved to be resistant to HLBI, effectiveness was 25% (CR 1 case, MR 2 cases, NC 6 cases, PD 3 cases). The results obtained indicated that OK-432 following IFN is a potentially active antitumor regimen in patients with advanced RCC.

摘要

肾细胞癌(RCC)是对放疗或抗癌化疗最不敏感的泌尿系统肿瘤之一。最近,有报道称干扰素(IFN)对RCC有效。然而,由于这种效果在一定程度上有限,需要一种新的治疗方式。我们在此报告我们对IFN和OK-432(一种链球菌制剂)用于晚期RCC患者的经验。20例年龄在26岁至75岁之间,平均年龄为52.3岁的患者进入本研究。每天肌肉注射剂量为3×10⁶单位的人淋巴母细胞干扰素(HLBI),持续4至76周。除非患者达到完全缓解(CR)或在初始HLBI治疗期间病情严重恶化,否则在HLBI治疗后接着使用OK-432。12例患者接受OK-432治疗,剂量为5KE(临床单位),每周2天,持续10至64周。HLBI治疗的有效率为20%(CR 1例,部分缓解[MR] 3例,病情稳定[NC] 11例,病情进展[PD] 5例)。对于对HLBI耐药的患者,辅助使用OK-432治疗,有效率为25%(CR 1例,MR 2例,NC 6例,PD 3例)。所获得的结果表明,IFN之后使用OK-432对晚期RCC患者是一种潜在有效的抗肿瘤方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验